August 2023 in “JAAD International” Low dose oral minoxidil is generally safe and can improve hair loss in women, with some experiencing side effects and minimal blood pressure changes.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” Dutasteride is the most effective for hair loss but may cause sexual and mental side effects.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
1 citations
,
October 2022 in “Iet Nanobiotechnology” The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.
May 2024 in “Reactions weekly”
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
January 2024 in “JEADV Clinical Practice” Patients with certain skin diseases are willing to spend significant time on treatment, indicating a high impact on their lives and a need for better treatments.
July 2024 in “Journal of Investigative Dermatology” The Fas/FasL pathway may play a role in alopecia areata.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” 1 citations
,
August 2022 in “Journal of Cosmetic Dermatology” Using both 5% spironolactone and 5% minoxidil together is safe and more effective for treating hair loss.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.
A new minoxidil regimen improved hair loss in a lupus patient.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
14 citations
,
May 2009 in “Journal of the American Academy of Dermatology” The patient's scalp lesions stabilized with a combination of treatments after initial therapies failed.
October 2024 in “Zagazig University Medical Journal” Transdermal delivery using a fractional CO2 laser is more effective for treating alopecia areata than injections.
November 2024 in “Actas Dermo-Sifiliográficas” Low-dose oral minoxidil can improve hair and eyebrow growth in frontal fibrosing alopecia.
December 2024 in “Journal of the European Academy of Dermatology and Venereology” Sublingual and oral minoxidil are equally effective for hair growth, but sublingual causes fewer palpitations.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
August 2016 in “Journal of Investigative Dermatology”
Follicular unit extraction is safe and effective without bupivacaine and nerve blocks when using lignocaine with adrenaline.
Hair loss treatment using stem cells from baby teeth was effective for 75% of men tested, with mild side effects. A scoring system may predict how well this treatment works.
April 2022 in “Journal of evolution of medical and dental sciences” Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.
January 2024 in “JEADV clinical practice” Patients were highly satisfied with shared medical appointments for hair loss treatment.
November 2022 in “Zenodo (CERN European Organization for Nuclear Research)” March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.